文献速递关节外科创伤骨科

无占位器两期全髋关节置换翻修术后的成功率及再感染危险因素:187例患者的前瞻性队列研究

Success Rate After 2-Stage Spacer-Free Total Hip Arthroplasty Exchange and Risk Factors for Reinfection: A Prospective Cohort Study of 187 Patients.
PubMed 文献 · J Arthroplasty · 2024-05-15

该前瞻性队列研究纳入2013至2019年187例因全髋关节置换术后慢性假体周围感染接受无占位器两期翻修术的患者,平均随访54.2±24.9个月,总体成功率为85.6%,再感染累积概率1年为11.5%、2年为14%,高毒力或难治病原体感染及既往两期髋关节假体翻修史是再感染的独立危险因素。

要点

  • 无占位器两期翻修术治疗全髋关节置换术后假体周围感染的总体成功率为85.6%。
  • 再感染累积概率为1年11.5%、2年14%,再手术率为26.2%,翻修率为16.6%。
  • 高毒力或难治病原体感染及既往两期髋关节假体翻修史是再感染的独立危险因素。

核心结论

  • 无占位器两期全髋关节置换翻修术治疗假体周围感染的再感染率仍较高,但与包含骨水泥占位器的方案相当。
  • 既往两期假体翻修失败或感染高毒力或难治病原体的患者治疗失败风险高。

研究设计与样本

  • 前瞻性队列研究,2013至2019年连续纳入187例因全髋关节置换术后假体周围感染接受无占位器两期翻修术的患者。
  • 平均随访54.2±24.9个月(范围36至96个月),两期之间平均间隔9.8±8.9周(范围2至38周)。
  • 两期治疗间所有患者均处于无占位器的Girdlestone状态。

主要发现

  • 总体成功率为85.6%。
  • 再感染累积概率为再植入后1年11.5%、2年14%。
  • 高毒力或难治病原体感染是再感染的显著独立危险因素(HR=3.71,95%CI:1.47至9.36,P=.006;HR=3.85,95%CI:1.73至8.57,P=.001)。
  • 既往两期髋关节假体翻修史是再感染的显著独立危险因素(HR=3.58,95%CI:1.33至9.62,P=.01)。
  • 总体再手术率和翻修率分别为26.2%和16.6%;再感染患者再手术概率比非感染患者高80%(P<.001,log-rank=102.6),随访期间接受翻修手术的可能性高55%(P<.001,log-rank=55.4)。

关键数值与推荐

  • 两期治疗后保持无感染状态定义为治疗成功。
  • 高毒力或难治病原体感染再感染HR=3.71(95%CI:1.47至9.36,P=.006)。
  • 难治病原体感染再感染HR=3.85(95%CI:1.73至8.57,P=.001)。
  • 既往两期髋关节假体翻修史再感染HR=3.58(95%CI:1.33至9.62,P=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two-stage prosthesis exchange is the treatment of choice for chronic periprosthetic joint infection (PJI) of a total hip arthroplasty (THA), especially when the bone and surrounding soft tissues are compromised or difficult-to-treat pathogens are implicated. The aims of our study were as follows: (1) to determine the outcome of 2-stage prosthesis exchange for the treatment of PJI after THA and (2) to determine the risk factors for reinfection leading to subsequent revision surgeries after reimplantation. METHODS: We prospectively enrolled 187 consecutive patients who underwent a 2-stage THA exchange with resection arthroplasty for PJI from 2013 to 2019. The mean (± SD) duration of follow-up was 54.2 ± 24.9 months (range, 36 to 96), and the mean interval until reimplantation was 9.8 ± 8.9 weeks (range, 2 to 38). All patients remained in a spacer-free girdlestone situation between the 2 stages of treatment. Patients who remained infection-free after their 2-stage treatment were considered to have achieved treatment success. RESULTS: The overall success rate was 85.6%. The cumulative probability of reinfection was 11.5% after one year and 14% after 2 years after reimplantation. High virulence or difficult-to-treat pathogens were significant and independent risk factors for reinfection (HR [hazard ratio] = 3.71, 95% CI [confidence interval]: 1.47 to 9.36, P = .006 and HR = 3.85, 95% CI: 1.73 to 8.57, respectively, P = .001), as was previous 2-stage hip prosthesis exchange (HR = 3.58, 95% CI: 1.33 to 9.62, P = .01). Overall reoperation and revision rates were 26.2 and 16.6%, respectively. Re-infected patients had an 80% higher probability of reoperation than noninfected ones (P < .001, log-rank = 102.6), and they were 55% more likely to undergo revision surgery during their follow-up (P < .001, log-rank = 55.4). CONCLUSIONS: Reinfection rates after 2-stage spacer-free THA revision for PJI still remain high but are comparable to those including cement spacers. Patients who have had prior failed 2-stage implant exchanges or are infected by high-grade or difficult-to-treat pathogens are at high risk for treatment failure.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Goumenos S, Hardt S, Kontogeorgakos V, et al. Success Rate After 2-Stage Spacer-Free Total Hip Arthroplasty Exchange and Risk Factors for Reinfection: A Prospective Cohort Study of 187 Patients. J Arthroplasty. 2024. PMID: 38759820. doi:10.1016/j.arth.2024.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。